Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
(sofosbuvir velpatasvir voxilaprevir)
78 results
  • Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C. [Review]
    Infect Drug Resist 2019; 12:2259-2268Childs-Kean LM, Brumwell NA, Lodl EF
  • The treatment of chronic hepatitis C has been revolutionized with the introduction of direct-acting antivirals (DAAs). However, some patients are not cured with first-line treatment. Sofosbuvir/velpatasvir/voxilaprevir is a fixed-dose combination of a polymerase inhibitor, an NS5A inhibitor, and a protease inhibitor with activity against strains of the hepatitis C virus that show resistance to ot…
  • Management of HCV patients in cases of direct-acting antiviral failure. [Journal Article]
    Expert Rev Gastroenterol Hepatol 2019; 13(9):839-848Hayes CN, Imamura M, Chayama K
  • Introduction: Over 70 million people are infected with hepatitis C virus (HCV), increasing the risk of cirrhosis and hepatocellular carcinoma. Areas covered: Since the approval of the first interferon-free direct-acting antiviral (DAA) therapy in 2011, a number of DAAs have been approved, and HCV is now considered curable. Until recently, however, there were no clear guidelines on how to re-treat…
New Search Next